• In early May 2026, Gilead Sciences reported first-quarter 2026 results showing revenue of US$6.96 billion and net income of US$2.02 billion, alongside updated guidance that pairs higher expected product sales with an adjusted full-year earnings loss driven by very large acquisition-related charges.

• At the same time, Gilead advanced its HIV portfolio with FDA priority review for the once-daily bictegravir/lenacapavir combination and continued returning capital through share repurchases, even as it filed a US$6.51 billion common stock shelf registration that could expand its financial flexibility.

• We’ll now examine how stronger HIV momentum but sharply lower earnings guidance from acquisition charges may reshape Gilead’s existing investment narrative.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Gilead Sciences Investment Narrative Recap

To own Gilead today, you need to believe its HIV engine and newer launches can offset policy pressures and future patent cliffs, while oncology gradually adds weight. The latest quarter reinforces that core HIV demand is still there, but the sharply lower full year earnings guidance from acquisition charges puts near term focus on execution and balance sheet use rather than on any single pipeline catalyst. That trade off, in my view, is now the central risk to watch.

Among the recent moves, the US$6.51 billion common stock shelf registration stands out alongside active buybacks. Together with higher 2026 product sales guidance, it underlines how management is keeping financial options open while absorbing large acquisition related charges. For investors following HIV and oncology catalysts, that extra flexibility could matter if upcoming FDA decisions or oncology launches require more capital than previously assumed.

Yet against these positives, investors should still be aware of how acquisition related charges and potential dilution could interact with policy and pricing pressure…

Read the full narrative on Gilead Sciences (it’s free!)

Gilead Sciences’ valuation narrative projects $33.6 billion in revenue and $10.9 billion in earnings by 2029.

Uncover how Gilead Sciences’ forecasts yield a $157.43 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Before this quarter, the most pessimistic analysts were assuming only about 2.4% annual revenue growth to roughly US$31.6 billion by 2029 and still worried that oncology competition and relatively flat HIV expectations might cap upside. This new set of results and guidance could either soften or reinforce that view, so it is worth comparing how your own expectations line up with those lower bar forecasts.